Barrett's oesophagus: From metaplasia to dysplasia and cancer

Gut

Volumn 54, Issue SUPPL. 1, 2005, Pages

  Flejou J F ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN; MUCIN;

BARRETT ESOPHAGUS; CANCER SCREENING; CARCINOGENESIS; CELL PROLIFERATION; CONFERENCE PAPER; DYSPLASIA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; ESOPHAGUS MUCOSA; HUMAN; HUMAN TISSUE; INTESTINE METAPLASIA; MALIGNANT TRANSFORMATION; METAPLASIA; PLOIDY; PRECANCER; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ANEUPLOIDY; BARRETT ESOPHAGUS; CELL TRANSFORMATION, NEOPLASTIC; DNA, NEOPLASM; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; MUCINS; MUCOUS MEMBRANE; NEOPLASMS, GLANDULAR AND EPITHELIAL; PRECANCEROUS CONDITIONS; RISK FACTORS;

EID: 14344264011     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2004.041525     Document Type: Conference Paper

References (66)

1. Sampliner RE. Practice guidelines on the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 1998;93:1028-31.
2. Haggitt RC. Adenocarcinoma in Barrett's esophagus: a new epidemic? Hum Pathol 1992;23:475-76.
3. Montgomery E, Goldblum JR, Greenson JK, et al. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study. Hum Pathol 2001;32:379-88.
4. Jankowski JA, Wright NA, Meltzer SJ, et al. Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Pathol 1999;154:965-73.
5. Werner M, Mueleer J, Walch A, et al. The molecular pathology of Barrett's esophagus. Histol Histopathol 1999;14:553-59.
6. Beilstein M, Silberg D. Cellular and molecular mechanisms responsible for progression of Barrett's metaplasia to esophageal carcinoma. Gastroenterol Clin North Am 2002;31:461-79.
7. Rustgi AK. Biomarkers for malignancy in the columnar-lined esophagus. Gastroenterol Clin North Am 1997;26:599-606.
8. Flejou JF, Chatelain D. Contribution of new tools to the characterization of Barrett mucosa. Gastroenterol Clin Biol 1999;23:B20-9.
9. Spechler SJ, Goyal RK. The columnar-lined esophagus, intestinal metaplasia and Norman Barrett. Gastroenterology 1996;110:614-21.
10. Sharma P, Morales TG, Sampliner RE. Short segment Barrett's esophagus - the need for standardization of the definition and endoscopic criteria. Am J Gastroenterol 1998;93:1033-6.
11. Paull A, Trier JS, Dalton MD, et al. The histologic spectrum of Barrett's esophagus. N Engl J Med 1976;295:476-80.
12. Zwas F, Shields HM, Doos WG, et al. Scanning electron microscopy of Barrett's epithelium and its correlation with light microscopy and mucin stains. Gastroenterology 1986;90:1932-41.
13. Hassall E. Columnar-lined esophagus in children. Gastroenterol Clin North Am 1997;26:533-48.
14. Oberg S, DeMeester TR, Peters JH, et al. The extent of Barrett's esophagus depends on the status of the lower esophageal sphincter and the degree of esophageal acid exposure. J Thorac Cardiovasc Surg 1999;117:572-80.
15. Cameron AJ, Carpenter HA. Barrett's esophagus, high-grade dysplasia, and early adenocarcinoma: a pathological study. Am J Gastroenterol 1997;92:586-91.
16. Chatelain D, Flejou JF. High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins. Virchows Arch 2003;442:18-24.
17. Peuchmaur M, Potet F, Goldfain D. Mucin histochemistry of the columnar epithelium of the oesophagus (Barrett's oesophagus): a prospective biopsy study. J Clin Pathol 1984;37:607-10.
18. Rothery GA, Patterson JE, Stoddard CJ, et al. Histological and histochemical changes in the columnar lined (Barrett's) oesophagus. Gut 1986;27:1062-68.
19. Genta RM, Huberman RM, Graham DY. The gastric cardia in Helicobacter pylori infection. Hum Pathol 1994;25:915-19.
20. Chen YY, Wang HH, Antonioli DA, et al. Significance of acid-mucin-positive nongoblet columnar cells in the distal esophagus and gastroesophageal junction. Hum Pathol 1999;30:1488-95.
21. Ormsby AH, Goldblum JR, Rice TW, et al. Cytokerotin subsets can reliably distinguish Barrett's esophagus from intestinal metaplasia of the stomach. Hum Pathol 1999;30:288-94.
22. Ormsby AH, Vaezi MF, Richter JE, et al. Cytokeratin immunoreactivity patterns in the diagnosis of short-segment Barrett's esophagus. Gastroenterology 2000;119:683-90.
23. Couvelard A, Cauvin JM, Goldfain D, et al. Cytokeratin immunoreactivity of intestinal metaplasia at normal oesophagogastric junction indicates its aetiology. Gut 2001;49:761-60.
24. Glickman JN, Wang H, Das KM, et al. Phenotype of Barrett's esophagus and intestinal metaplasia of the distal esophagus and gastroesophageal junction: an immunohistochemical study of cytokeratins 7 and 20, Das-1 and 45 M1. Am J Surg Pathol 2001;25:87-94.
25. El-Zimaity HM, Graham DY. Cytokeratin subsets for distinguishing Barrett's esophagus from intestinal metaplasia in the cardia using endoscopic biopsy specimens. Am J Gastroenterol 2001;96:1378-82.
26. Mohammed IA, Streutker CJ, Riddell RH. Utilization of cytokeratins 7 and 20 does not differentiate between Barrett's esophagus and gastric cardiac intestinal metaplasia. Mod Pathol 2002;15:611-16.
27. DeMeester SR, Wickramasinghe KS, Lord RV, et al. Cytokeratin and DAS-1 immunostaining reveal similarities among cardiac mucosa, CIM, and Barrett's esophagus. Am J Gastroenterol 2002;97:2514-23.
28. Chinyama CN, Marshall RE, Owen WJ, et al. Expression of MUC1 and MUC2 mucin gene products in Barrett's metaplasia, dysplasia and adenocarcinoma: an immunopathological study with clinical correlation. Histopathology 1999;35:517-24.
29. Guillem P, Billeret V, Buisine MP, et al. Mucin gene expression and cell differentiation in human normal, premalignant and malignant esophagus. Int J Cancer 2000;88:856-61.
30. Geboes K, Van Eyken P. The diagnosis of dysplasia and malignancy in Barrett's osophagus. Histopathology 2000;37:99-107.
31. Riddell RH, Goldman H, Ransohoff DF, et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol 1983;14:931-68.
32. Schmidt HG, Riddell RH, Walther B, et al. Dysplasia in Barrett's esophagus. J Cancer Res Clin Oncol 1985;110:145-52.
33. Werner M, Flejou JF, Hainaut P, et al. Adenocarcinoma of the oesophagus. In: Hamilton SR, Aaltonen LA, eds. Pathology and genetics of tumours of the digestive system. Lyon: IARC Press, 2000:20-6.
34. Faller G, Borchard F, Ell C, et al. Histopathological diagnosis of Barrett's mucosa and associated neoplasias: results of a consensus conference of the working group for gastroenterological pathology of the German Society for Pathology on 22 September 2001 in Erlangen. Virchows Arch 2003;443:597-601.
35. Offerhaus GJA, Correa P, van Eeden S, et al. Report of an Amsterdam working group on Barrett esophagus. Virchows Arch 2003;443:601-7.
36. Goldblum JR, Lauwers GY. Dysplasia arising in Barrett's esophagus: diagnostic pitfalls and natural history. Semin Diagn Pathol 2002;19:12-19.
37. Montgomery E, Bronner MP, Goldblum JR, et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol 2001;32:368-78.
38. Reid BJ, Haggitt RC, Rubin CE, et al. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol 1988;19:166-78.
39. Sagan C, Fléjou J-F, Diebold MD, et al. Reproductibilité des critères histologiques de dysplasie sur muqueuse de Barrett. Gastroenterol Clin Biol 1994;18:D31-4.
40. Alikhan M, Rex D, Khan A, et al. Variable pathologic interpretation of columnar lined esophagus by general pathologists in community practice. Gastrointest Endosc 1999;50:23-26.
41. Ormsby AH, Petras RE, Hendricks WH, et al. Interobserver variation in Barrett's related high grade dysplasia and superficial carcinoma: can it be improved using uniform pathological criteria? Gut 2002;51:671-6.
42. Schlemper RJ, Riddell RH, Kato Y, et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 2000;47:251-5.
43. Heilmiller RF, Redmond M, Hamilton SR. Barrett's esophagus with high grade dysplasia. An indication for prophylactic esophagectomy. Ann Surg 1996;224:60-71.
44. Falk GW, Rice TW, Goldblum JR, et al. Jumbo biopsy forceps protocol still misses unsuspected cancer in Barrett's esophagus with high-grade dysplasia. Gastrointest Endosc 1999;49:170-6.
45. Levine DS, Haggitt RC, Blount PL, et al. An endoscopic biopsy protocol can differentiate hign-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology 1993;105:40-50.
46. Schnell TG, Sontag SJ, Chejfec G, et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 2001;120:1607-19.
47. Levine DS, Haggitt RC, Irvine S. Natural history of high-grade dysplasia in Barrett's esophagus [abstract]. Gastroenterology 1996;110:A550.
48. Weston AP, Sharma P, Topalovski M, et al. Long-term follow-up of Barrett's high-grade dysplasia. Am J Gastroenterol 2000;95:1888-93.
49. Buttar NS, Wang KK, Sebo TJ, et al. Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology 2001;120:1630-9.
50. Dar MS, Goldblum JR, Rice TW, et al. Can extent of high grade dysplasia in Barrett's oesophagus predict the presence of adenocarcinoma at oesophagectomy? Gut 2003;52:486-9.
51. Thurberg BL, Duray PH, Odze RD. Polypoid dysplasia in Barrett's esophagus: a clinicopathologic, immunohistochemical, and molecular study of five cases. Hum Pathol 1999;30:745-52.
52. Skacel M, Petras R, Gramlich T, et al. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression. Am J Gastroenterol 2000;95:3383-7.
53. Morales CP, Souza RF, Spechler SJ. Hallmarks of cancer progression in Barrett's oesophagus. Lancet 2002;360:1587-9.
54. Wijnhoven BP, Tilanus HW, Dinjens WN. Molecular biology of Barrett's adenocarcinoma. Ann Surg 2001;233:322-37.
55. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
56. Reid BJ, Blount PL, Rubin CE, et al. Flow cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology 1992;102:1212-19.
57. Reid BJ, Levine DS, Longton G, et al. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 2000;95:1669-76.
58. Teodori L, Gohde W, Persiani M, et al. DNA/protein flow cytometry as a predictive marker of malignancy in dysplasia-free Barrett's esophagus: thirteen-year follow-up study on a conort of patients. Cytometry 1998;34:257-63.
59. Fennerty MB, Sampliner RE, Way D, et al. Discordance between flow cytometry abnormalities and dysplasia in Barrett's esophagus. Gastroenterology 1989;97:815-20.
60. Hong MK, Laskin WB, Herman BE, et al. Expansion of the Ki-67 proliferative compartment correlates with degree of dysplasia in Barrett's esophagus. Cancer 1995;75:423-9.
61. Filzgerald RC, Omary MB, Triadafilopoulos G. Dynamic effects of acid on Barrett's esophagus. J Clin Invest 1996;98:2120-8.
62. Peters FTM, Ganesh S, Kuipers EJ, et al. Effect of elimination of acid reflux on epithelial cell proliferative activity of Barrett esophagus. Scand J Gastroenterol 2000;35:1238-44.
63. Kim R, Clarke MR, Melhem MF, et al. Expression of p53, PCNA, and C-erbB-2 in Barrett's metaplasia and adenocarcinoma. Dig Dis Sci 1997;42:2453-62.
64. Younes M, Ertan A, Lechago LV, et al. p53 protein accumulation is a specific marker of malignant potential in Barrett's metaplasia. Dig Dis Sci 1997;42:697-701.
65. Weston AP, Banerjee SK, Sharma P, et al. p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: immunohistochemical marker predictive of progression. Am J Gastroenterol 2001;96:1355-62.
66. Selaru FM, Zou T, Xu Y, et al. Global gene expression profiling in Barrett's esophagus and esophageal cancer: a comparative analysis using cDNA microarrays. Oncogene 2002;21:475-8.